Ruthenium(II) Polypyridyl Complexes for Antimicrobial Photodynamic Therapy: Prospects for Application in Cystic Fibrosis Lung Airways
Antimicrobial photodynamic therapy (aPDT) depends on a variety of parameters notably related to the photosensitizers used, the pathogens to target and the environment to operate. In a previous study using a series of Ruthenium(II) polypyridyl ([Ru(II)]) complexes, we reported the importance of the c...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/8/1664 |
| _version_ | 1827617635774234624 |
|---|---|
| author | Raphaëlle Youf Adeel Nasir Mareike Müller Franck Thétiot Tanguy Haute Rosy Ghanem Ulrich Jonas Holger Schönherr Gilles Lemercier Tristan Montier Tony Le Gall |
| author_facet | Raphaëlle Youf Adeel Nasir Mareike Müller Franck Thétiot Tanguy Haute Rosy Ghanem Ulrich Jonas Holger Schönherr Gilles Lemercier Tristan Montier Tony Le Gall |
| author_sort | Raphaëlle Youf |
| collection | DOAJ |
| description | Antimicrobial photodynamic therapy (aPDT) depends on a variety of parameters notably related to the photosensitizers used, the pathogens to target and the environment to operate. In a previous study using a series of Ruthenium(II) polypyridyl ([Ru(II)]) complexes, we reported the importance of the chemical structure on both their photo-physical/physico-chemical properties and their efficacy for aPDT. By employing standard in vitro conditions, effective [Ru(II)]-mediated aPDT was demonstrated against planktonic cultures of <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> strains notably isolated from the airways of Cystic Fibrosis (CF) patients. CF lung disease is characterized with many pathophysiological disorders that can compromise the effectiveness of antimicrobials. Taking this into account, the present study is an extension of our previous work, with the aim of further investigating [Ru(II)]-mediated aPDT under in vitro experimental settings approaching the conditions of infected airways in CF patients. Thus, we herein studied the isolated influence of a series of parameters (including increased osmotic strength, acidic pH, lower oxygen availability, artificial sputum medium and biofilm formation) on the properties of two selected [Ru(II)] complexes. Furthermore, these compounds were used to evaluate the possibility to photoinactivate <i>P. aeruginosa</i> while preserving an underlying epithelium of human bronchial epithelial cells. Altogether, our results provide substantial evidence for the relevance of [Ru(II)]-based aPDT in CF lung airways. Besides optimized nano-complexes, this study also highlights the various needs for translating such a challenging perspective into clinical practice. |
| first_indexed | 2024-03-09T09:50:50Z |
| format | Article |
| id | doaj.art-4ae796bf5835497f8b116f507c6f3135 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T09:50:50Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-4ae796bf5835497f8b116f507c6f31352023-12-02T00:10:00ZengMDPI AGPharmaceutics1999-49232022-08-01148166410.3390/pharmaceutics14081664Ruthenium(II) Polypyridyl Complexes for Antimicrobial Photodynamic Therapy: Prospects for Application in Cystic Fibrosis Lung AirwaysRaphaëlle Youf0Adeel Nasir1Mareike Müller2Franck Thétiot3Tanguy Haute4Rosy Ghanem5Ulrich Jonas6Holger Schönherr7Gilles Lemercier8Tristan Montier9Tony Le Gall10INSERM, Univ Brest, EFS, UMR 1078, GGB-GTCA, 29200 Brest, FranceINSERM, Univ Brest, EFS, UMR 1078, GGB-GTCA, 29200 Brest, FrancePhysical Chemistry I & Research Center of Micro- and Nanochemistry and (Bio)Technology (Cμ), Department of Chemistry and Biology, University of Siegen, 57076 Siegen, GermanyUnité Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS) 6521, Université de Brest (UBO), CS 93837, 29238 Brest, FranceINSERM, Univ Brest, EFS, UMR 1078, GGB-GTCA, 29200 Brest, FranceINSERM, Univ Brest, EFS, UMR 1078, GGB-GTCA, 29200 Brest, FranceMacromolecular Chemistry, Department of Chemistry and Biology, University of Siegen, 57076 Siegen, GermanyPhysical Chemistry I & Research Center of Micro- and Nanochemistry and (Bio)Technology (Cμ), Department of Chemistry and Biology, University of Siegen, 57076 Siegen, GermanyCoordination Chemistry Team, Unité Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS) 7312, Institut de Chimie Moléculaire de Reims (ICMR), Université de Reims Champagne-Ardenne, BP 1039, CEDEX 2, 51687 Reims, FranceINSERM, Univ Brest, EFS, UMR 1078, GGB-GTCA, 29200 Brest, FranceINSERM, Univ Brest, EFS, UMR 1078, GGB-GTCA, 29200 Brest, FranceAntimicrobial photodynamic therapy (aPDT) depends on a variety of parameters notably related to the photosensitizers used, the pathogens to target and the environment to operate. In a previous study using a series of Ruthenium(II) polypyridyl ([Ru(II)]) complexes, we reported the importance of the chemical structure on both their photo-physical/physico-chemical properties and their efficacy for aPDT. By employing standard in vitro conditions, effective [Ru(II)]-mediated aPDT was demonstrated against planktonic cultures of <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> strains notably isolated from the airways of Cystic Fibrosis (CF) patients. CF lung disease is characterized with many pathophysiological disorders that can compromise the effectiveness of antimicrobials. Taking this into account, the present study is an extension of our previous work, with the aim of further investigating [Ru(II)]-mediated aPDT under in vitro experimental settings approaching the conditions of infected airways in CF patients. Thus, we herein studied the isolated influence of a series of parameters (including increased osmotic strength, acidic pH, lower oxygen availability, artificial sputum medium and biofilm formation) on the properties of two selected [Ru(II)] complexes. Furthermore, these compounds were used to evaluate the possibility to photoinactivate <i>P. aeruginosa</i> while preserving an underlying epithelium of human bronchial epithelial cells. Altogether, our results provide substantial evidence for the relevance of [Ru(II)]-based aPDT in CF lung airways. Besides optimized nano-complexes, this study also highlights the various needs for translating such a challenging perspective into clinical practice.https://www.mdpi.com/1999-4923/14/8/1664antimicrobial photodynamic therapyantimicrobial resistancebiofilmbenchmark analysiscystic fibrosismicro-environment |
| spellingShingle | Raphaëlle Youf Adeel Nasir Mareike Müller Franck Thétiot Tanguy Haute Rosy Ghanem Ulrich Jonas Holger Schönherr Gilles Lemercier Tristan Montier Tony Le Gall Ruthenium(II) Polypyridyl Complexes for Antimicrobial Photodynamic Therapy: Prospects for Application in Cystic Fibrosis Lung Airways Pharmaceutics antimicrobial photodynamic therapy antimicrobial resistance biofilm benchmark analysis cystic fibrosis micro-environment |
| title | Ruthenium(II) Polypyridyl Complexes for Antimicrobial Photodynamic Therapy: Prospects for Application in Cystic Fibrosis Lung Airways |
| title_full | Ruthenium(II) Polypyridyl Complexes for Antimicrobial Photodynamic Therapy: Prospects for Application in Cystic Fibrosis Lung Airways |
| title_fullStr | Ruthenium(II) Polypyridyl Complexes for Antimicrobial Photodynamic Therapy: Prospects for Application in Cystic Fibrosis Lung Airways |
| title_full_unstemmed | Ruthenium(II) Polypyridyl Complexes for Antimicrobial Photodynamic Therapy: Prospects for Application in Cystic Fibrosis Lung Airways |
| title_short | Ruthenium(II) Polypyridyl Complexes for Antimicrobial Photodynamic Therapy: Prospects for Application in Cystic Fibrosis Lung Airways |
| title_sort | ruthenium ii polypyridyl complexes for antimicrobial photodynamic therapy prospects for application in cystic fibrosis lung airways |
| topic | antimicrobial photodynamic therapy antimicrobial resistance biofilm benchmark analysis cystic fibrosis micro-environment |
| url | https://www.mdpi.com/1999-4923/14/8/1664 |
| work_keys_str_mv | AT raphaelleyouf rutheniumiipolypyridylcomplexesforantimicrobialphotodynamictherapyprospectsforapplicationincysticfibrosislungairways AT adeelnasir rutheniumiipolypyridylcomplexesforantimicrobialphotodynamictherapyprospectsforapplicationincysticfibrosislungairways AT mareikemuller rutheniumiipolypyridylcomplexesforantimicrobialphotodynamictherapyprospectsforapplicationincysticfibrosislungairways AT franckthetiot rutheniumiipolypyridylcomplexesforantimicrobialphotodynamictherapyprospectsforapplicationincysticfibrosislungairways AT tanguyhaute rutheniumiipolypyridylcomplexesforantimicrobialphotodynamictherapyprospectsforapplicationincysticfibrosislungairways AT rosyghanem rutheniumiipolypyridylcomplexesforantimicrobialphotodynamictherapyprospectsforapplicationincysticfibrosislungairways AT ulrichjonas rutheniumiipolypyridylcomplexesforantimicrobialphotodynamictherapyprospectsforapplicationincysticfibrosislungairways AT holgerschonherr rutheniumiipolypyridylcomplexesforantimicrobialphotodynamictherapyprospectsforapplicationincysticfibrosislungairways AT gilleslemercier rutheniumiipolypyridylcomplexesforantimicrobialphotodynamictherapyprospectsforapplicationincysticfibrosislungairways AT tristanmontier rutheniumiipolypyridylcomplexesforantimicrobialphotodynamictherapyprospectsforapplicationincysticfibrosislungairways AT tonylegall rutheniumiipolypyridylcomplexesforantimicrobialphotodynamictherapyprospectsforapplicationincysticfibrosislungairways |